The use of substituted tetracyclic imidazole derivatives as anti-histaminics

The invention concerns the use of an H1- and/or H2-histamine receptor antagonist for the reduction of intracranial pressure (ICP), in particular for the prevention and treatment of elevated intracranial pressure and/or secondary ischaemia, in particular caused by brain injury, more in particular cau...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: BARTOLOME-NEBREDA JOSE MANUEL, VAN REEMPTS JOZEF LEO HENRI, LEENAERTS JOSEPH ELISABETH, ALCAZAR-VACA MANUEL JESUS, VAN ROSSEM KOENRAAD ARTHUR, FERNANDEZ-GADEA FRANCISCO JAVIER, MARTINEZ-JIMENEZ PEDRO, GOMEZ-SANCHEZ ANTONIO, TEGTMEIER FRANK, JANSSENS FRANS EDUARD
Format: Patent
Sprache:eng ; hun
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator BARTOLOME-NEBREDA JOSE MANUEL
VAN REEMPTS JOZEF LEO HENRI
LEENAERTS JOSEPH ELISABETH
ALCAZAR-VACA MANUEL JESUS
VAN ROSSEM KOENRAAD ARTHUR
FERNANDEZ-GADEA FRANCISCO JAVIER
MARTINEZ-JIMENEZ PEDRO
GOMEZ-SANCHEZ ANTONIO
TEGTMEIER FRANK
JANSSENS FRANS EDUARD
description The invention concerns the use of an H1- and/or H2-histamine receptor antagonist for the reduction of intracranial pressure (ICP), in particular for the prevention and treatment of elevated intracranial pressure and/or secondary ischaemia, in particular caused by brain injury, more in particular caused by traumatic (TBI) and non-traumatic brain injury. In particular, the histamine antagonist is selected from the group of acrivastine, alimemazine, antazoline, astemizole, azatadine, azelastine, brompheniramine, buclizine, carbinoxamine, carebastine, cetirizine, chlorcyclizine, chlorpheniramine, cinnarizine, clemastine, clemizole, clocinizine, clonidine, cyclizine, cyproheptadine, descarboethoxyloratidine, dexchlorpheniramine, dimenhydrinate, dimethindene, dimethothiazine, diphenhydramine, diphenylpyraline, doxylamine, ebastine, efletirizine, epinastine, fexofenadine, hydroxyzine, ketotifen, levocabastine, loratidine, meclizine, mequitazine, methdilazine, mianserin, mizolastine, niaprazine, noberastine, norastemizole, oxatomide, oxomemazine, phenbenzamine, pheniramine, picumast, promethazine, pyrilamine, temelastine, terfenadine, trimeprazine, tripelennamine, triprolidine, ranitidine, cimetidine, famotidine, nizatidine, tiotidine, zolantidine, ritanserine, and derivatives thereof and mixtures of any two or more of the foregoing.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_HU229118B1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>HU229118B1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_HU229118B13</originalsourceid><addsrcrecordid>eNqFyjEKwkAQRuE0FqKewblAio2NtoqSwjLWYdz9QwY22ZCZDejptbAXHnzNWxf3pgdlBaWOND_VxLIhkMFm9i8fxZMMEvidIihgloVNFijxt9Gk7EWNBxnF67ZYdRwVu5-bYn-7Npe6xJRa6MQeI6ytH1V1cu54dof_xwcVgjXA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>The use of substituted tetracyclic imidazole derivatives as anti-histaminics</title><source>esp@cenet</source><creator>BARTOLOME-NEBREDA JOSE MANUEL ; VAN REEMPTS JOZEF LEO HENRI ; LEENAERTS JOSEPH ELISABETH ; ALCAZAR-VACA MANUEL JESUS ; VAN ROSSEM KOENRAAD ARTHUR ; FERNANDEZ-GADEA FRANCISCO JAVIER ; MARTINEZ-JIMENEZ PEDRO ; GOMEZ-SANCHEZ ANTONIO ; TEGTMEIER FRANK ; JANSSENS FRANS EDUARD</creator><creatorcontrib>BARTOLOME-NEBREDA JOSE MANUEL ; VAN REEMPTS JOZEF LEO HENRI ; LEENAERTS JOSEPH ELISABETH ; ALCAZAR-VACA MANUEL JESUS ; VAN ROSSEM KOENRAAD ARTHUR ; FERNANDEZ-GADEA FRANCISCO JAVIER ; MARTINEZ-JIMENEZ PEDRO ; GOMEZ-SANCHEZ ANTONIO ; TEGTMEIER FRANK ; JANSSENS FRANS EDUARD</creatorcontrib><description>The invention concerns the use of an H1- and/or H2-histamine receptor antagonist for the reduction of intracranial pressure (ICP), in particular for the prevention and treatment of elevated intracranial pressure and/or secondary ischaemia, in particular caused by brain injury, more in particular caused by traumatic (TBI) and non-traumatic brain injury. In particular, the histamine antagonist is selected from the group of acrivastine, alimemazine, antazoline, astemizole, azatadine, azelastine, brompheniramine, buclizine, carbinoxamine, carebastine, cetirizine, chlorcyclizine, chlorpheniramine, cinnarizine, clemastine, clemizole, clocinizine, clonidine, cyclizine, cyproheptadine, descarboethoxyloratidine, dexchlorpheniramine, dimenhydrinate, dimethindene, dimethothiazine, diphenhydramine, diphenylpyraline, doxylamine, ebastine, efletirizine, epinastine, fexofenadine, hydroxyzine, ketotifen, levocabastine, loratidine, meclizine, mequitazine, methdilazine, mianserin, mizolastine, niaprazine, noberastine, norastemizole, oxatomide, oxomemazine, phenbenzamine, pheniramine, picumast, promethazine, pyrilamine, temelastine, terfenadine, trimeprazine, tripelennamine, triprolidine, ranitidine, cimetidine, famotidine, nizatidine, tiotidine, zolantidine, ritanserine, and derivatives thereof and mixtures of any two or more of the foregoing.</description><language>eng ; hun</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2013</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20130828&amp;DB=EPODOC&amp;CC=HU&amp;NR=229118B1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20130828&amp;DB=EPODOC&amp;CC=HU&amp;NR=229118B1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>BARTOLOME-NEBREDA JOSE MANUEL</creatorcontrib><creatorcontrib>VAN REEMPTS JOZEF LEO HENRI</creatorcontrib><creatorcontrib>LEENAERTS JOSEPH ELISABETH</creatorcontrib><creatorcontrib>ALCAZAR-VACA MANUEL JESUS</creatorcontrib><creatorcontrib>VAN ROSSEM KOENRAAD ARTHUR</creatorcontrib><creatorcontrib>FERNANDEZ-GADEA FRANCISCO JAVIER</creatorcontrib><creatorcontrib>MARTINEZ-JIMENEZ PEDRO</creatorcontrib><creatorcontrib>GOMEZ-SANCHEZ ANTONIO</creatorcontrib><creatorcontrib>TEGTMEIER FRANK</creatorcontrib><creatorcontrib>JANSSENS FRANS EDUARD</creatorcontrib><title>The use of substituted tetracyclic imidazole derivatives as anti-histaminics</title><description>The invention concerns the use of an H1- and/or H2-histamine receptor antagonist for the reduction of intracranial pressure (ICP), in particular for the prevention and treatment of elevated intracranial pressure and/or secondary ischaemia, in particular caused by brain injury, more in particular caused by traumatic (TBI) and non-traumatic brain injury. In particular, the histamine antagonist is selected from the group of acrivastine, alimemazine, antazoline, astemizole, azatadine, azelastine, brompheniramine, buclizine, carbinoxamine, carebastine, cetirizine, chlorcyclizine, chlorpheniramine, cinnarizine, clemastine, clemizole, clocinizine, clonidine, cyclizine, cyproheptadine, descarboethoxyloratidine, dexchlorpheniramine, dimenhydrinate, dimethindene, dimethothiazine, diphenhydramine, diphenylpyraline, doxylamine, ebastine, efletirizine, epinastine, fexofenadine, hydroxyzine, ketotifen, levocabastine, loratidine, meclizine, mequitazine, methdilazine, mianserin, mizolastine, niaprazine, noberastine, norastemizole, oxatomide, oxomemazine, phenbenzamine, pheniramine, picumast, promethazine, pyrilamine, temelastine, terfenadine, trimeprazine, tripelennamine, triprolidine, ranitidine, cimetidine, famotidine, nizatidine, tiotidine, zolantidine, ritanserine, and derivatives thereof and mixtures of any two or more of the foregoing.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2013</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqFyjEKwkAQRuE0FqKewblAio2NtoqSwjLWYdz9QwY22ZCZDejptbAXHnzNWxf3pgdlBaWOND_VxLIhkMFm9i8fxZMMEvidIihgloVNFijxt9Gk7EWNBxnF67ZYdRwVu5-bYn-7Npe6xJRa6MQeI6ytH1V1cu54dof_xwcVgjXA</recordid><startdate>20130828</startdate><enddate>20130828</enddate><creator>BARTOLOME-NEBREDA JOSE MANUEL</creator><creator>VAN REEMPTS JOZEF LEO HENRI</creator><creator>LEENAERTS JOSEPH ELISABETH</creator><creator>ALCAZAR-VACA MANUEL JESUS</creator><creator>VAN ROSSEM KOENRAAD ARTHUR</creator><creator>FERNANDEZ-GADEA FRANCISCO JAVIER</creator><creator>MARTINEZ-JIMENEZ PEDRO</creator><creator>GOMEZ-SANCHEZ ANTONIO</creator><creator>TEGTMEIER FRANK</creator><creator>JANSSENS FRANS EDUARD</creator><scope>EVB</scope></search><sort><creationdate>20130828</creationdate><title>The use of substituted tetracyclic imidazole derivatives as anti-histaminics</title><author>BARTOLOME-NEBREDA JOSE MANUEL ; VAN REEMPTS JOZEF LEO HENRI ; LEENAERTS JOSEPH ELISABETH ; ALCAZAR-VACA MANUEL JESUS ; VAN ROSSEM KOENRAAD ARTHUR ; FERNANDEZ-GADEA FRANCISCO JAVIER ; MARTINEZ-JIMENEZ PEDRO ; GOMEZ-SANCHEZ ANTONIO ; TEGTMEIER FRANK ; JANSSENS FRANS EDUARD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_HU229118B13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; hun</language><creationdate>2013</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>BARTOLOME-NEBREDA JOSE MANUEL</creatorcontrib><creatorcontrib>VAN REEMPTS JOZEF LEO HENRI</creatorcontrib><creatorcontrib>LEENAERTS JOSEPH ELISABETH</creatorcontrib><creatorcontrib>ALCAZAR-VACA MANUEL JESUS</creatorcontrib><creatorcontrib>VAN ROSSEM KOENRAAD ARTHUR</creatorcontrib><creatorcontrib>FERNANDEZ-GADEA FRANCISCO JAVIER</creatorcontrib><creatorcontrib>MARTINEZ-JIMENEZ PEDRO</creatorcontrib><creatorcontrib>GOMEZ-SANCHEZ ANTONIO</creatorcontrib><creatorcontrib>TEGTMEIER FRANK</creatorcontrib><creatorcontrib>JANSSENS FRANS EDUARD</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>BARTOLOME-NEBREDA JOSE MANUEL</au><au>VAN REEMPTS JOZEF LEO HENRI</au><au>LEENAERTS JOSEPH ELISABETH</au><au>ALCAZAR-VACA MANUEL JESUS</au><au>VAN ROSSEM KOENRAAD ARTHUR</au><au>FERNANDEZ-GADEA FRANCISCO JAVIER</au><au>MARTINEZ-JIMENEZ PEDRO</au><au>GOMEZ-SANCHEZ ANTONIO</au><au>TEGTMEIER FRANK</au><au>JANSSENS FRANS EDUARD</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>The use of substituted tetracyclic imidazole derivatives as anti-histaminics</title><date>2013-08-28</date><risdate>2013</risdate><abstract>The invention concerns the use of an H1- and/or H2-histamine receptor antagonist for the reduction of intracranial pressure (ICP), in particular for the prevention and treatment of elevated intracranial pressure and/or secondary ischaemia, in particular caused by brain injury, more in particular caused by traumatic (TBI) and non-traumatic brain injury. In particular, the histamine antagonist is selected from the group of acrivastine, alimemazine, antazoline, astemizole, azatadine, azelastine, brompheniramine, buclizine, carbinoxamine, carebastine, cetirizine, chlorcyclizine, chlorpheniramine, cinnarizine, clemastine, clemizole, clocinizine, clonidine, cyclizine, cyproheptadine, descarboethoxyloratidine, dexchlorpheniramine, dimenhydrinate, dimethindene, dimethothiazine, diphenhydramine, diphenylpyraline, doxylamine, ebastine, efletirizine, epinastine, fexofenadine, hydroxyzine, ketotifen, levocabastine, loratidine, meclizine, mequitazine, methdilazine, mianserin, mizolastine, niaprazine, noberastine, norastemizole, oxatomide, oxomemazine, phenbenzamine, pheniramine, picumast, promethazine, pyrilamine, temelastine, terfenadine, trimeprazine, tripelennamine, triprolidine, ranitidine, cimetidine, famotidine, nizatidine, tiotidine, zolantidine, ritanserine, and derivatives thereof and mixtures of any two or more of the foregoing.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; hun
recordid cdi_epo_espacenet_HU229118B1
source esp@cenet
subjects CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title The use of substituted tetracyclic imidazole derivatives as anti-histaminics
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T13%3A36%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=BARTOLOME-NEBREDA%20JOSE%20MANUEL&rft.date=2013-08-28&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EHU229118B1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true